Page last updated: 2024-12-09

1-[1-methyl-2-(1-pyrrolidinylmethyl)-5-benzimidazolyl]-3-phenylurea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

The compound you described, 1-[1-methyl-2-(1-pyrrolidinylmethyl)-5-benzimidazolyl]-3-phenylurea, is a synthetic molecule with a complex structure involving a benzimidazole ring, a pyrrolidine ring, and a urea functional group. It's not commonly known by a specific name like a drug or a natural product.

**Here's why it might be important for research:**

* **Potential Biological Activity:** The combination of these functional groups suggests potential for biological activity. For instance, benzimidazole derivatives are often found in compounds with antifungal, antiviral, and antiparasitic properties. The pyrrolidine ring is frequently present in molecules that interact with receptors in the nervous system, and the urea group can participate in hydrogen bonding interactions, which are important for drug-target interactions.
* **Lead Compound for Drug Discovery:** This molecule could serve as a starting point for drug discovery research. By modifying its structure through chemical synthesis, scientists could explore its potential to interact with specific biological targets and develop drugs with desired therapeutic effects.
* **Structure-Activity Relationship Studies:** Researchers might use this compound to investigate the structure-activity relationship of benzimidazole derivatives. By changing the substituents on the benzimidazole ring or modifying the other functional groups, they could study how these changes affect its biological activity.

**Important Note:** Without further context or specific research focus, it's impossible to definitively state why this specific compound is important. It could be a theoretical structure used for teaching purposes, a compound with potential therapeutic applications under investigation, or a molecule used in a specific research project.

**To understand its significance, you need to consider:**

* **The research context:** What is the specific area of research?
* **The research objectives:** What is the purpose of studying this molecule?
* **The experimental methods:** How is the compound being studied or used?

If you have more information about the context, I can provide a more detailed explanation.

Cross-References

ID SourceID
PubMed CID1253604
CHEMBL ID1386145
CHEBI ID108024

Synonyms (16)

Synonym
MLS000100003 ,
smr000081656
n-[1-methyl-2-(1-pyrrolidinylmethyl)-1h-benzimidazol-5-yl]-n'-phenylurea
CHEBI:108024
AKOS001847039
MLS002548276
1-[1-methyl-2-(pyrrolidin-1-ylmethyl)benzimidazol-5-yl]-3-phenylurea
1-[1-methyl-2-(pyrrolidin-1-ylmethyl)-1h-benzimidazol-5-yl]-3-phenylurea
STK796211
HMS2470E17
CHEMBL1386145
Q27186455
1-[1-methyl-2-(1-pyrrolidinylmethyl)-5-benzimidazolyl]-3-phenylurea
3-{1-methyl-2-[(pyrrolidin-1-yl)methyl]-1h-1,3-benzodiazol-5-yl}-1-phenylurea
SR-01000296114-1
sr-01000296114
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
ureas
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00250.003245.467312,589.2998AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency2.81840.044717.8581100.0000AID485294
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency3.98110.125919.1169125.8920AID2549
BRCA1Homo sapiens (human)Potency11.22020.89137.722525.1189AID624202
ATAD5 protein, partialHomo sapiens (human)Potency14.81120.004110.890331.5287AID504466; AID504467
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency18.88760.707912.194339.8107AID720542
P53Homo sapiens (human)Potency50.11870.07319.685831.6228AID504706
survival motor neuron protein isoform dHomo sapiens (human)Potency7.94330.125912.234435.4813AID1458
Guanine nucleotide-binding protein GHomo sapiens (human)Potency50.11871.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]